Tempus ECG-Low EF vs Fetal EchoScan

Tempus ECG-Low EF is designed to integrate into healthcare facility workflows, analyzing 12-lead ECG recordings to provide a binary output (Low LVEF Detected/Not Detected) that aids clinicians in further evaluation. Tempus plans to integrate ECG-Low EF into existing clinical workflows, enabling scalable deployment across hospitals and outpatient settings, and is focusing on partnerships with electronic health record (EHR) providers to ensure seamless implementation. Fetal EchoScan integrates seamlessly with existing ultrasound workflows and reporting solutions, being DICOM compatible. It provides real-time guidance and alerts on a cart-side tablet display during scans, optimizing workflow and ensuring exam completeness.

Tempus ECG-Low EF was trained on a large dataset of over 930,000 ECGs from more than 170,000 patients to detect signs associated with low LVEF (u226440%) in patients 40 years or older at risk of heart failure. An external validation showed the model achieved 85.8% sensitivity and 83.0% specificity. Fetal EchoScan detects suspicious findings with high sensitivity and high specificity, and had a conclusive output regarding the presence of any finding for 98.8% of exams in standalone testing. It aims to reduce false-negative and false-positive errors in congenital heart defect detection by providing AI-driven support and real-time guidance during prenatal ultrasound examinations.

Tempus ECG-Low EF is most useful in cardiology, emergency medicine, and internal medicine settings for identifying patients 40+ years at risk of heart failure, including those with atrial fibrillation, aortic stenosis, cardiomyopathy, myocardial infarction, diabetes, hypertension, mitral regurgitation, and ischemic heart disease, by analyzing resting 12-lead ECGs for signs of low LVEF. Fetal EchoScan offers significant utility in maternal-fetal medicine, cardiology, and radiology for prenatal detection of congenital heart defects during second-trimester anatomic ultrasound exams in pregnant women aged 18 or older. It helps ensure comprehensive exams and optimizes workflow during ultrasound screenings.

For Tempus ECG-Low EF, the learning curve would likely focus on interpreting the binary output (Low LVEF Detected/Not Detected) and integrating it into existing diagnostic pathways, as the software analyzes ECGs and provides a clear result. Tempus emphasizes the necessity of integrating AI into clinicians' existing workflows without adding complexity. Fetal EchoScan provides real-time guidance and feedback during ultrasound scans via a cart-side tablet display, suggesting an intuitive integration into existing ultrasound workflows. Training would likely focus on leveraging the automated detection and guidance features to ensure exam completeness and standardization.

Tempus ECG-Low EF can offer rapid time-to-value by quickly identifying patients at risk of heart failure from routine ECGs, potentially streamlining the diagnostic pathway for low LVEF and aiding in earlier intervention. Fetal EchoScan aims for fast time-to-value by optimizing workflow, reducing false-negative and false-positive errors, and ensuring exam completeness during prenatal ultrasound examinations, leading to faster reading times and more standardized fetal heart assessments.

For multi-site rollout, Tempus ECG-Low EF would require integrating the software into diverse ECG acquisition and reporting systems across different healthcare facility workflows, ensuring consistent data input and output. Tempus aims for scalable deployment across hospitals and outpatient settings through EHR partnerships. Scaling Fetal EchoScan across multiple sites would involve integrating with various existing ultrasound machines and reporting solutions, leveraging its DICOM compatibility, with its cart-side tablet display offering flexible deployment.